Literature DB >> 10197598

Core-binding factor: a central player in hematopoiesis and leukemia.

N A Speck1, T Stacy, Q Wang, T North, T L Gu, J Miller, M Binder, M Marín-Padilla.   

Abstract

Consistent chromosomal rearrangements are found in a large number of hematopoietic tumors. In many cases, these rearrangements disrupt genes whose normal function is required for the proper development of blood cells. Excellent examples are the chromosomal rearrangements t(8;21)(q22;q22), t(12;21)(p13;q22), and inv(16)(p13q22) that disrupt two of the genes encoding a small family of heterodimeric transcription factors, core-binding factors (CBFs). CBFs consist of a DNA-binding CBFalpha subunit and a non-DNA-binding CBFbeta subunit. The t(8;21), associated with de novo acute myeloid leukemias, disrupts the CBFA2 (AML1) gene, which encodes a DNA-binding CBFalpha subunit. The t(12;21), the most common translocation in pediatric acute lymphocytic leukemias, also disrupts CBFA2. The CBFB gene, which encodes the non-DNA-binding subunit of the CBFs, is disrupted by the inv(16) in de novo acute myeloid leukemias. All chromosomal rearrangements involving the CBFA2 and CBFB genes create chimeric proteins, two of which have been unequivocally demonstrated to function as transdominant negative inhibitors of CBF function. Both the Cbfa2 and Cbfb genes are essential for normal hematopoiesis in mice, because homozygous disruption of either gene blocks definitive hematopoiesis. Recent data suggest that Cbfa2 and Cbfb are required for the emergence of definitive hematopoietic stem cells in the embryo from a putative definitive hemangioblast precursor. The transdominant negative inhibitor of CBF created by the inv(16), when present from the beginning of embryogenesis, also blocks the emergence of definitive hematopoietic cells in the embryo. On the other hand, chromosomal translocations involving the CBFA2 and CBFB genes in leukemias block hematopoiesis at later steps. This may reflect a difference in the timing at which translocations are acquired in the leukemias, which presumably is subsequent to emergence of the definitive hematopoietic stem cell. The cumulative data suggest that although the earliest requirement for Cbfa2 and Cbfb is for emergence of definitive hematopoietic stem cells, both genes are also required at later stages in the differentiation of some hematopoietic lineages.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10197598

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  32 in total

1.  Mitotic partitioning and selective reorganization of tissue-specific transcription factors in progeny cells.

Authors:  Sayyed K Zaidi; Daniel W Young; Shirwin M Pockwinse; Amjad Javed; Jane B Lian; Janet L Stein; Andre J van Wijnen; Gary S Stein
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-01       Impact factor: 11.205

2.  Biological characteristics of the leukemia-associated transcriptional factor AML1 disclosed by hematopoietic rescue of AML1-deficient embryonic stem cells by using a knock-in strategy.

Authors:  T Okuda; K Takeda; Y Fujita; M Nishimura; S Yagyu; M Yoshida; S Akira; J R Downing; T Abe
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

Review 3.  Megakaryocyte biology and related disorders.

Authors:  Liyan Pang; Mitchell J Weiss; Mortimer Poncz
Journal:  J Clin Invest       Date:  2005-12       Impact factor: 14.808

4.  Regulation of platelet myosin light chain (MYL9) by RUNX1: implications for thrombocytopenia and platelet dysfunction in RUNX1 haplodeficiency.

Authors:  Gauthami Jalagadugula; Guangfen Mao; Gurpreet Kaur; Lawrence E Goldfinger; Danny N Dhanasekaran; A Koneti Rao
Journal:  Blood       Date:  2010-09-27       Impact factor: 22.113

5.  Subnuclear targeting of Runx/Cbfa/AML factors is essential for tissue-specific differentiation during embryonic development.

Authors:  J Y Choi; J Pratap; A Javed; S K Zaidi; L Xing; E Balint; S Dalamangas; B Boyce; A J van Wijnen; J B Lian; J L Stein; S N Jones; G S Stein
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

6.  RUNX1 permits E4orf6-directed nuclear localization of the adenovirus E1B-55K protein and associates with centers of viral DNA and RNA synthesis.

Authors:  Leslie J Marshall; Amy C Moore; Misao Ohki; Issay Kitabayashi; David Patterson; David A Ornelles
Journal:  J Virol       Date:  2008-04-16       Impact factor: 5.103

7.  The t(1;12)(q21;p13) translocation of human acute myeloblastic leukemia results in a TEL-ARNT fusion.

Authors:  F Salomon-Nguyen; V Della-Valle; M Mauchauffe; M Busson-Le Coniat; J Ghysdael; R Berger; O A Bernard
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

Review 8.  Regain control of p53: Targeting leukemia stem cells by isoform-specific HDAC inhibition.

Authors:  Ya-Huei Kuo; Jing Qi; Guerry J Cook
Journal:  Exp Hematol       Date:  2016-02-26       Impact factor: 3.084

9.  Dichotomy of AML1-ETO functions: growth arrest versus block of differentiation.

Authors:  S A Burel; N Harakawa; L Zhou; T Pabst; D G Tenen; D E Zhang
Journal:  Mol Cell Biol       Date:  2001-08       Impact factor: 4.272

Review 10.  Steroid resistance in leukemia.

Authors:  Darshan S Shah; Raj Kumar
Journal:  World J Exp Med       Date:  2013-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.